Cover Image
市場調查報告書

孤兒藥的全球市場:產業分析與預測

Global Orphan Drugs Market- Industry Analysis & Outlook 2017-2021

出版商 Koncept Analytics 商品編碼 351312
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
孤兒藥的全球市場:產業分析與預測 Global Orphan Drugs Market- Industry Analysis & Outlook 2017-2021
出版日期: 2017年06月27日 內容資訊: 英文 67 Pages
簡介

本報告提供全球孤兒藥 (罕見疾病治療藥)的市場最新趨勢與未來展望相關分析,孤兒藥的整體市場結構和趨勢預測,各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業簡介、業績、策略等相關調查與考察。

第1章 概要

第2章 全球孤兒藥市場

  • 孤兒藥市場收益
  • 孤兒藥市場收益預測
  • 孤兒藥的各產品市場
  • 處方藥市場上孤兒藥的佔有率
  • 處方藥市場上孤兒藥的佔有率的預測

第3章 各地區的分析

  • 南北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞洲
    • 日本
    • 印度

第4章 市場動態

  • 成長因素
  • 主要趨勢
  • 課題

第5章 競爭環境

  • 全球市場
  • 歐洲市場

第6章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

An orphan disease refers to any rare disease which affects a smaller portion of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.

Orphan drug market is likely to witness a growth in future with the increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The U.S. and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan designations. Asia is likely to experience further growth with increasing drug approvals in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends of this market include progressing drug pipeline, rising treatment options in oncology and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.

The report "Global Orphan Drugs Market: Industry Analysis & Outlook (2017-2021)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, Europe and Asia along with the global market. The report profiles key players of the market including Roche, Novartis, Bristol-Myers Squibb and Celgene.

Table of Contents

1. Overview

  • 1.1 Orphan Disease
  • 1.2 Orphan Drugs

2. Global Orphan Drugs Market

  • 2.1 Orphan Drugs Market Value
  • 2.2 Orphan Drugs Market Forecast by Value
  • 2.3 Orphan Drugs Market by Product
  • 2.4 Orphan Drugs Share in Prescription Drugs Market
  • 2.5 Orphan Drugs Share Forecast in Prescription Drugs Market

3. Regional Markets

  • 3.1 The Americas
    • 3.1.1 The U.S Orphan Drugs Spending Forecast
    • 3.1.2 The U.S. Orphan Drug Volume
    • 3.1.3 The U.S. Orphan Drug Average & Median Cost per Patient
    • 3.1.4 The U.S. Orphan Drug Average & Median Cost per Patient Forecast
    • 3.1.5 Canada Orphan Drugs Spending
    • 3.1.6 Canada Orphan Drugs Spending Forecast
  • 3.2 Europe
    • 3.2.1 Europe Orphan Drugs Market Forecast by Value
    • 3.2.2 Europe Orphan Drugs Market by Product
    • 3.2.3 Europe Orphan Drug Volume
  • 3.3 Asia
    • 3.3.1 Japan Orphan Drug Volume
    • 3.3.2 India Orphan Drugs Market Value Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Prolonged Orphan Drug Market Exclusivity
    • 4.1.2 Increasing Sales of Prescription Drugs
    • 4.1.3 Attractive Orphan Drug Policies
    • 4.1.4 Rising Healthcare Expenditure
    • 4.1.5 Improving Economic Condition
    • 4.1.6 Increasing Prevalence of Chronic Diseases
  • 4.2 Key Trends
    • 4.2.1 Progressing Drug Pipeline
    • 4.2.2 Increasing Treatment Options in Oncology
    • 4.2.3 Increasing Scope of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Cost Drugs
    • 4.3.2 Lack of Diagnostic Systems and Trained Professionals
    • 4.3.3 Insufficient Disease Information and Research Participants
    • 4.3.4 Rising Competition from Generic Industry

5. Competition

  • 5.1 Global Market
    • 5.1.1 Global Orphan Drugs Market Share by Company
  • 5.2 Europe
    • 5.2.1 Europe Orphan Drugs Market Share by Company

6. Company Profiles

  • 6.1 Roche
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Novartis
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Bristol-Myers Squibb
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Celgene
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Types of Orphan Drugs
  • Orphan Drug Development
  • Global Orphan Drugs Market by Value (2012-2016)
  • Global Orphan Drugs Market Forecast by Value (2017-2021)
  • Global Orphan Drugs Market by Product (2016)
  • Global Orphan Drugs Share in Prescription Drugs Market (2012-2016)
  • Global Orphan Drugs Share Forecast in Prescription Drugs Market (2017-2021)
  • The U.S. Orphan Drugs Spending Forecast (2016-2021)
  • The U.S. Orphan Drug Volume (2012-2016)
  • The U.S. Orphan Drug Average & Median Cost per Patient (2012-2016)
  • The U.S. Orphan Drug Average & Median Cost per Patient Forecast (2017-2021)
  • Canada Orphan Drugs Spending (2012-2016)
  • Canada Orphan Drugs Spending Forecast (2017-2021)
  • Europe Orphan Drugs Market Forecast by Value (2016-2021)
  • Europe Orphan Drugs Market by Product (2016)
  • Europe Orphan Drug Volume (2012-2016)
  • Japan Orphan Drug Volume (2012-2016)
  • India Orphan Drugs Market Value Forecast (2016-2021)
  • Global Prescription Drugs Sales (2012-2016)
  • Global Healthcare Expenditure Per Capita (2012-2016)
  • Global GDP Per Capita (2012-2016)
  • Global Cancer Prevalence (2012-2030E)
  • Global Orphan Drugs Market Share by Company (2016)
  • Europe Orphan Drugs Market Share by Company (2016)
  • Roche Sales by Segment (2016)
  • Roche Sales and Net Income (2012-2016)
  • Roche R&D Expenditure (2014-2016)
  • Novartis Sales by Segment (2016)
  • Novartis Net Sales and Net Income (2012-2016)
  • Novartis R&D Expenditure (2014-2016)
  • Bristol-Myers Squibb Revenue by Segment (2016)
  • Bristol-Myers Squibb Total Revenue and Net Earnings (2012-2016)
  • Bristol-Myers Squibb R&D Expenditure (2014-2016)
  • Celgene Revenue by Region (2016)
  • Celgene Total Revenue and Net Income (2012-2016)
  • Celgene R&D Expenditure (2014-2016)

List of Tables

  • Orphan Disease Prevalence in Different Nations
  • Orphan Drug Market Exclusivity
  • Orphan Drug Policies
  • Orphan Drugs Under Development (2016)
Back to Top